Intercell AG / other / Intercell Finalizes Submission of US Biological License Application (BLA) To FDA For Licensure ... (n-tv.de)
-------------------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.

AMAG Pharmaceuticals, Inc. Submits New Drug Application To FDA For Ferumoxytol In Chronic Kidney Disease Patients (Medical News Today)
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for marketing approval of ferumoxytol as an intravenous treatment of iron deficiency anemia in patients with chronic kidney disease (CKD), including dialysis dependent and non-dialysis dependent patients. [click link for full article]